TREM2

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Retrieved on: 
Wednesday, March 6, 2024

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 in an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases being held March 5 – March 9 in Lisbon Portugal.

Key Points: 
  • WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 in an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases being held March 5 – March 9 in Lisbon Portugal.
  • The presentation outlines preclinical data on the agonist pharmacology of VG-3927, its effect on AD-associated neuropathological endpoints, and its potential as a disease-modifying therapeutic for the treatment of AD.
  • “As the first and only small molecule TREM2 agonist to enter clinical development, we are thrilled to have an opportunity to further demonstrate the differentiated profile for VG-3927 and how it could represent a significant treatment advancement for those living with AD,” said David Gray, PhD, Chief Science Officer at Vigil.
  • “Having recently commenced dosing in our Phase 1 healthy volunteer clinical trial evaluating VG-3927, we look forward to further investigating this mechanism of action and its potential as a disease-modifying therapeutic.”
    Title: Characterization of the First Small Molecule TREM2 Agonist, VG-3927, for Clinical Development in Alzheimer’s Disease

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.

Orphan designation: Human IgG1 (296-cysteine,301-glycine,306-cysteine) monoclonal antibody against TREM2 Treatment of CSF1R-related leukoencephalopathy, 13/10/2023 Positive

Retrieved on: 
Sunday, February 4, 2024

Key facts

Key Points: 
  • Key facts
    - Active substance
    - Human IgG1 (296-cysteine,301-glycine,306-cysteine) monoclonal antibody against TREM2
    - Intended use
    - Treatment of CSF1R-related leukoencephalopathy
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2847
    - Date of designation
    - Sponsor
    Pharma Gateway AB
    Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

Retrieved on: 
Wednesday, January 3, 2024

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today provided a 2023 year-in-review and outlined key milestones anticipated in 2024. The Company also today announced that it has extended its projected cash runway into the second half of 2025.

Key Points: 
  • ET -
    WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today provided a 2023 year-in-review and outlined key milestones anticipated in 2024.
  • “2023 marked a year of persistent advancement and landmark achievements for the Company,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.
  • “Most notably, we were the first company to demonstrate clinical data supporting TREM2 agonism as a potential therapeutic approach in neurodegenerative disease.
  • “We enter 2024 well-positioned to achieve our planned value-driving milestones across our development pipeline,” concluded Dr. Magovčević-Liebisch.

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Retrieved on: 
Tuesday, November 28, 2023

SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs.

Key Points: 
  • SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs.
  • The events will include presentations from Alector’s management as well as leading scientific and clinical experts who will provide their perspectives on the biological and genetic rationale for the TREM2 and PGRN targets, share an overview of the current treatment landscapes for frontotemporal dementia and Alzheimer’s disease, and discuss the significant unmet needs that remain in the treatment of these neurodegenerative diseases.
  • To access the live webcasts of these events, please register here for TREM2 and here for PGRN, or visit “Events and Presentations” in the “Investors” section of the Alector website at https://investors.alector.com .
  • An archived replay will be available for approximately 90 days following each presentation.

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

Retrieved on: 
Thursday, November 16, 2023

"The positive interim results from our Phase 2 IGNITE trial represent the first clinical data reported from an interventional study in patients with ALSP and reaffirm our belief in the potential of iluzanebart as a novel treatment option.

Key Points: 
  • "The positive interim results from our Phase 2 IGNITE trial represent the first clinical data reported from an interventional study in patients with ALSP and reaffirm our belief in the potential of iluzanebart as a novel treatment option.
  • Key Highlights from Phase 2 IGNITE Interim Data:
    Favorable safety and tolerability profile, including no hematologic adverse events.
  • We believe the quality and consistency of the interim data further support the continuation of IGNITE without modification.
  • Interim Montreal Cognitive Assessment (MoCA) and Cortical Basal Ganglia Functional Scale data support use as clinical endpoints in ALSP at 12 months.

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent progress.

Key Points: 
  • In September, we also proudly introduced our oral small molecule TREM2 agonist candidate, VG-3927, with the opening of our IND.
  • Cash Position: Cash, cash equivalents, and marketable securities were $133.6 million as of September 30, 2023, compared to $150.2 million as of June 30, 2023.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter ended September 30, 2023, were $6.9 million, compared to $4.8 million for the same period in 2022.
  • Net Loss: Loss from operations for the third quarter ended September 30, 2023, were $20.5 million, compared to $17.5 million for the same period in 2022.

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported third quarter 2023 financial results and recent portfolio and business updates. As of September 30, 2023, Alector’s cash, cash equivalents and investments totaled $588.9 million.

Key Points: 
  • “We’ve made significant clinical advancements in our late-stage immuno-neurology programs in the second half of 2023,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.
  • In September 2023, Alector completed enrollment in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial, with data anticipated in the fourth quarter of 2024.
  • Collaboration revenue for the quarter ended September 30, 2023, was $9.1 million, compared to $14.9 million for the same period in 2022.
  • Total research and development expenses for the quarter ended September 30, 2023, were $46.3 million, compared to $48.3 million for the quarter ended September 30, 2022.

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, October 17, 2023

“Dosing the first participant in our Phase 1 trial of VG-3927, the first and only small molecule TREM2 agonist in clinical development for assessment in AD, is an important milestone in our multi-modality strategy to develop novel therapeutics for the treatment of rare and common neurodegenerative diseases,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.

Key Points: 
  • “Dosing the first participant in our Phase 1 trial of VG-3927, the first and only small molecule TREM2 agonist in clinical development for assessment in AD, is an important milestone in our multi-modality strategy to develop novel therapeutics for the treatment of rare and common neurodegenerative diseases,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.
  • “With approximately 6.7 million Americans living with AD, there remains a significant need for new therapies with improved safety and efficacy and that can broadly address multiple aspects of AD disease pathophysiology.
  • The study is designed to evaluate VG-3927’s safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).
  • The Company anticipates reporting interim Phase 1 topline data in mid-2024.

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

Retrieved on: 
Monday, September 11, 2023

WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the complete data analysis from its VGL101 Phase 1 single and multiple ascending dose (SAD and MAD) healthy volunteer trial in a poster presentation at the 2023 American Neurological Association (ANA) Annual Meeting. In addition, the Company presented a poster highlighting the study design for its ongoing IGNITE Phase 2 clinical trial.

Key Points: 
  • In addition, the Company presented a poster highlighting the study design for its ongoing IGNITE Phase 2 clinical trial.
  • “The dataset from the VGL101 Phase 1 healthy volunteer trial is very encouraging and further validates our development strategy for the ongoing IGNITE Phase 2 trial in ALSP.
  • “We are committed to achieving further milestones for VGL101, including the interim data readout from IGNITE in the fourth quarter of 2023.
  • In a separate poster at the ANA Annual Meeting, the Company presented the trial design for its ongoing Phase 2 IGNITE trial.